Marina Kremyanskaya, MD, PhD | Authors


CPI-0610 Demonstrates Activity in Patients With Myelofibrosis After Ruxolitinib Failure

July 31, 2019

Marina Kremyanskaya, MD, PhD, discusses unique findings from the phase II trial investigating the effect of CPI-0610, a bromodomain and extra-terminal protein inhibitor, as treatment for patients with myelofibrosis who previously progressed on ruxolitinib.